GoodRx has partnered with Novo Nordisk to offer GLP-1 receptor agonists Ozempic and Wegovy at a cash price of $499 per month to eligible self-paying patients, marking the first reduced price point for these popular obesity and diabetes medications. This collaboration aims to improve affordability and expand patient access amid surging demand. GoodRx leverages its extensive consumer base and platform reach to provide meaningful savings and facilitate medication adherence.